Bertrand Delsuc

@BertrandBio

Just a curious guy / Launched , a business intel service on listed European Biotechs / Views=owner's only, RT-like=/=endorse, no advice

Lyon, France
biotechradar.eu
Vrijeme pridruživanja: travanj 2015.
4.524 fotografije ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @BertrandBio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BertrandBio

  1. Prikvačeni tweet
    9. sij

    My 2019 review for the European bios is out, with a short outlook for 2020. Check it out.⬇

    📰Our review of 2019 is out, with a short outlook of 2020 for the 🇪🇺European listed biotech landscape. European listed biotech landscape: 2019 review and outlook for 2020
    3 proslijeđena tweeta 6 korisnika označava da im se sviđa
    Poništi
  2. prije 3 sata

    There's not only the New and the New today, there's also the New ve Biotech in Stockholm :)

    Active Biotech announces new direction
    2 proslijeđena tweeta 1 korisnik označava da mu se sviđa
    Poništi
  3. prije 3 sata

    It seems Feng Zhang's Tx will make quite an IPO.

    Gene editing biotech Beam Therapeutics upsizes proposed IPO share offering by 48%
    2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
    Poništi
  4. prije 3 sata

    anecdotal but -116 now STT-5058 anti-ApoC3 mAb (apparently w/ same pH dependency trick than efgartigimod) about to enter the clinics this year, now virtually in the hands of (via a Staten Biotech sub-licensing option deal signed in Dec 2018)

    2 proslijeđena tweeta 3 korisnika označavaju da im se sviđa
    Poništi
  5. prije 5 sati

    Spin-off is the new M&A

    4 proslijeđena tweeta 9 korisnika označava da im se sviđa
    Poništi
  6. proslijedio/la je Tweet
    prije 5 sati

    to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (“NewCo”)

    7 proslijeđenih tweetova 7 korisnika označava da im se sviđa
    Poništi
  7. proslijedio/la je Tweet
    prije 5 sati

    FY'19 Worldwide Sales $46.8 Billion. Q4'19 Worldwide Sales $11.9 Billion. KEYTRUDA FY'19 Worldwide Sales Grew 55% to $11.1 Billion.

    3 proslijeđena tweeta 6 korisnika označava da im se sviđa
    Poništi
  8. prije 6 sati

    congrats for the nice series B

    French cancer-focused microbiome player is flush with €18M Series B injection
    1 korisnik označava da mu se sviđa
    Poništi
  9. prije 20 sati

    btw Bioeq IP withdrew their BLA, otherwise they've received an RTF

    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  10. prije 20 sati

    small setback for , ~4mo delay on Lucentis biosimilar BLA submitted by Bioeq

    Formycon informs about the current Status of the BLA Review Process of the Lucentis(R)* Biosimilar C...
    1 reply 1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  11. prije 20 sati

    FY19 CAR-T sales: Yescarta 456m$ vs Kymriah 278 m$

    1 reply 4 proslijeđena tweeta 20 korisnika označava da im se sviđa
    Poništi
  12. proslijedio/la je Tweet
    prije 22 sata

    FDA Guidance MPS III development /$LYSGF ESteve ...

    1 reply 5 proslijeđenih tweetova 18 korisnika označava da im se sviđa
    Poništi
  13. proslijedio/la je Tweet
    4. velj

    Happy to contribute to this work by Dotti lab, where was one of the models that was tested! IL23 helps CAR T cell function in solid tumors!

    Interleukin-23 engineering improves CAR T cell function in solid tumors
    Prikaži ovu nit
    11 proslijeđenih tweetova 29 korisnika označava da im se sviđa
    Poništi
  14. 4. velj

    AI-designed drug to enter human clinical trial for first time ( has stakes in Exscientia)

    Poništi
  15. 4. velj

    🇧🇪Galapagos new ATH +7.4% (nothing special either), retaking the lead from

    1 reply 4 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  16. 4. velj

    🇸🇪 .nicum +27% in Stockholm based on strictly nothing, 0 new data in ASCO-SITC abstract, the actual updated data won't bring anything really new so, I don't know what the investors speculate about.

    1 korisnik označava da mu se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    4. velj

    More than 100 clinical trials of neoadjuvant anti–PD-(L)1 blockade are ongoing. In this review check out the potential advantages of such an approach, including potential mechanisms for enhacing systemic antitumor T cell immunity after neoadj tt.

    65 proslijeđenih tweetova 136 korisnika označava da im se sviđa
    Poništi
  18. 3. velj

    apparently MSKCC intends to test a mesothelin CAR-T (CD28z) w/ PD-1 dominant-negative receptors this year in clinics (trial already ongoing for meso CAR-T+ anti-PD-1 mAb)

    2 korisnika označavaju da im se sviđa
    Poništi
  19. proslijedio/la je Tweet
    3. velj

    Whoa, that NEJM report from Germany claiming asymptomatic transmission of turned out to be wrong The index patient did have symptoms while in Germany. German RKI has written a letter to NEJM to set the record straight

    NEJM report from Germany formally documents first case of asymptomatic transmission of during the incubation period
    13 replies 67 proslijeđenih tweetova 143 korisnika označavaju da im se sviđa
    Poništi
  20. proslijedio/la je Tweet
    3. velj

    The latest Sugarcone Biotech post explores new horizons on the changing landscape. A must read.

    10 proslijeđenih tweetova 33 korisnika označavaju da im se sviđa
    Poništi
  21. 3. velj

    After French Cell4Cure acquired by last year, here's another acquisition of a European Cell Therapy player, with Belgian's MaSTherCell

    Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform
    1 reply 1 proslijeđeni tweet 1 korisnik označava da mu se sviđa
    Poništi

@BertrandBio još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·